# A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

> **NCT04527250** · PHASE1 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ASC41
- **DRUG:** ASC41 placebo

## Key facts

- **NCT ID:** NCT04527250
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-16
- **Primary completion:** 2020-12-18
- **Final completion:** 2020-12-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04527250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04527250, "A Study of the Relative Bioavailability of ASC41 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04527250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*